UTHR
← full report
United Therapeutics Corporation
Healthcare · Drug Manufacturers - Specialty & Generic
Made on
Aug 18, 2026
Price at call
$508.48
6-month call
Bear -5.0%
Target by Feb 2027
$483.00
Great value below
$425.00
Model
v0.6.0
Projection vs Actual (6M history + forecast)
Forecast Change
-5.0% to $483.00
Predicted High
$506.00
in 2 weeks
Predicted Low
$483.00
at 6 months
Max Drawdown (predicted)
-5.0%
Forecast
The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded. Predicted Aug 18, 2026 3:07 am
Bear
UTHR trends lower to
$483.00
(-5.0% from $508.48)
by Feb 2027.
decay
ThesisUTHR trades slightly above composite fair value with low beta and no near-term catalysts; expect drift lower toward the $479 anchor before stabilizing, with the moonshot narrative providing a soft floor around DCF value.
Invalidated ifBreak above $535 on Tyvaso volume acceleration or Miromatrix milestone; conversely break below $455 invalidates the floor thesis.
| Checkpointtime after the call | Datewhen it gets graded | Predictedthe claim: closing price | Current priceactual close — fills in over time | Predicted returnpredicted vs $508.48 at call | Conv.brain's confidence, 1–10 | Driverwhy the brain put the point here |
|---|---|---|---|---|---|---|
| Prediction made | Aug 18, 2026 | — | $508.48 at call | — | — | The anchor — every point below is measured from this price and date. |
| 2 weeks | Sep 1, 2026 | $488.38–$528.58 typical range · internal point $506.00 | — | ±4.0% | 6/10 | Low-vol drift, no catalyst, slight mean reversion |
| 1 month | Sep 18, 2026 | $479.35–$537.61 typical range · internal point $501.50 | — | ±5.7% | 6/10 | Value gravity begins pulling toward composite fair value |
| 2 months | Oct 18, 2026 | $495.00 | — | -2.7% | 5/10 | Q3 print approaches; anticipation muted, drift continues |
| 3 months | Nov 18, 2026 | $492.00 | — | -3.2% | 4/10 | Earnings likely beat but guidance caps upside |
| 4 months | Dec 18, 2026 | $488.00 | — | -4.0% | 4/10 | Year-end positioning, tax loss avoided given flat return |
| 5 months | Jan 18, 2027 | $485.00 | — | -4.6% | 3/10 | Converges toward signal-adjusted fair value anchor |
| 6 months | Feb 18, 2027 | $483.00 | — | -5.0% | 3/10 | Settles near composite FV, pipeline optionality holds floor |
Why ranges on the short rungs?
A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here —
three prompt formulations all lost to simply predicting zero — while the stock's own
volatility scale (σ×√t) described those windows well. So the short rungs claim what's
actually knowable: the typical travel, with earnings timing flagged where the variance
will come from. The internal point calls keep being generated and graded to map where
real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.
Deterministic control (v0.3 value line) targets $512.69 (+0.8%) — both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it. Brain: claude-opus-4-7.
Weaknesses
No weaknesses recorded for this run.All inputs present, no fallbacks used — nothing to flag.
Equation Inputs
Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.Value anchors (from deep analysis)
| Price at call | $508.48 |
| Composite fair value | $479.59 |
| Signal-adjusted fair value | $485.47 |
| DCF fair value | $464.12 |
| Anchored-PE fair value | $659.03 |
| Buy-below (value lens) | $425.00 |
| Value net score | -28 |
| Value confidence | 7 / 10 |
| Quality net score | +63 |
| Memo confidence | 7 / 10 |
| Deserved value (base) | — |
| Quality tilt | — |
| Deserved value (used) | — |
| Coherence (value × quality) | — |
Price behaviour (trailing — shapes the realism line)
| Realized volatility (annualized) | 1m 20.3% 3m 19.8% 6m 36.8% |
| Daily σ (realism noise) | 1.3% |
| Beta vs S&P 500 | 1m -0.23 3m -0.20 5m 0.13 |
| Trailing 6-month return | 7.3% |
Knobs (equation params)
| ladder | Array |
| llm_model | claude-opus-4-7 |
| max_tokens | 3000 |
| control_knobs | Array |
| Neutral band (%) | 5 |
| earnings_brief | v1 |
| prompt_version | p1 |
| control_version | v0.3.0 |
Version & Tech Chain
What produced this prediction — stamped on the record so versions can be compared by success rate later.
Model
v0.6.0
#271041f8fcd5 Tech composition (what this version is built from)
| # | Process | Kind | Group |
|---|---|---|---|
| 1 | Synthesis valuation-synthesis |
deterministic | final |
| 2 | Scenario Analysis scenario-valuation |
deterministic | valuation |
| 3 | Valuation / Mispricing ext-lens-value |
llm | extended |
| 4 | Company Quality ext-lens-quality |
llm | extended |
| 5 | Forensic Memo (combiner) ext-forensic-memo |
llm | extended |
| 6 | Classification company-classification |
llm | foundation |
| 7 | Live Quote fmp-quote |
data | market-data |
Inputs used (the runs that fed this prediction)
| Upstream process | Ran | Lag | Run id |
|---|---|---|---|
company-classification |
Jul 30, 2026 | 17d behind | UTHR-20260730-182637-5f33 |
ext-forensic-memo |
Aug 17, 2026 | freshest | ext-UTHR-20260817-131138-c578 |
ext-lens-quality |
Aug 17, 2026 | freshest | ext-UTHR-20260817-131138-c578 |
ext-lens-sentiment |
Aug 17, 2026 | freshest | ext-UTHR-20260817-131138-c578 |
ext-lens-value |
Aug 17, 2026 | freshest | ext-UTHR-20260817-131138-c578 |
scenario-valuation |
Aug 17, 2026 | freshest | UTHR-20260730-182637-5f33 |
valuation-synthesis |
Aug 17, 2026 | freshest | UTHR-20260730-182637-5f33 |
Inputs flagged 7d+ behind the freshest one may be stale relative to the rest of the analysis.
Saved History
2 frozen snapshots — the record we score once predictions mature.| Made | Model | Call | At call | Target | Exp. | Eval due | |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | v0.6.0 | Bear | $508.48 | $483.00 | -5.0% | Feb 2027 | viewing |
| Aug 1, 2026 | v0.6.0 | Bull | $517.71 | $565.00 | +9.1% | Feb 2027 | view |
Not Yet Modeled
What this v0.6.0 forecast deliberately ignores — the work ahead, in plain sight.- Scenario probabilities — one path, no bull/bear split (base_prob = 1.0).
- Intraday / sub-2-week behaviour — the first claim is at 14 days by design (EOD product).
- Position sizing / portfolio context — the path is a price claim only.